Sumitomo's Xenleta approved in China

22 November 2023

Japanese drugmaker Sumitomo Pharma (TYO: 4506) has received approval from China’s National Medical Products Administration (NMPA) for the use of Xenleta (lefamulin acetate) to treat adults with community-acquired pneumonia in injection and tablet formulation.

Xenleta is a pleuromutilin antimicrobial agent discovered and developed by Sandoz spin-out Nabriva Therapeutics (OTCMKTS: NBRVF). The drug’s entire development program was designed and executed by the Ireland-based infectious diseases specialist, which has since closed down, becoming the latest antibiotic developer to fail commercially.

The product was initially in-licensed and then acquired by Sumitomo in the geographies of China, Taiwan, Hong Kong, and Macau.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK